UCB invests $221m to construct a gene therapy facility

UCB will construct a gene therapy and clinical manufacturing plant at its campus in Braine l’Alleud, Wallonia, Belgium.

Millie Nelson, Editor

March 14, 2022

2 Min Read
UCB invests $221m to construct a gene therapy facility
Image: Stock Photo Secrets

UCB will construct a gene therapy and clinical manufacturing plant at its campus in Braine l’Alleud, Wallonia, Belgium.

According to UCB, the evolution of the gene therapy space has altered how diseases are being treated but the production of viral vectors remains a consistent challenge because of the complex manufacturing process. Therefore, developing capabilities and flexible manufacturing is critical to succeeding in the gene therapy industry.

To establish an end-to-end process, Belgium’s biggest drug maker has decided to invest more than €200 million ($221 million) to build an environmentally sustainable gene therapy process development and clinical manufacturing facility.

ISS_2972_11977-300x226.jpg

Image: Stock Photo Secrets

Construction of the 17,000 square meter facility is expected to begin during the second quarter of 2022 and is expected to be operational in 2024.

“Upon completion of our new gene therapy development and clinical manufacturing facility, UCB will have complete ownership and control of its chemistry, manufacturing, and controls (CMC) capabilities,” Kirsten Lund-Jurgensen, executive vice president and head of Supply & Technology Solutions at UCB said.

“This will enable agility, flexibility, unparalleled product and process understanding, scalability, and yield improvements, all translating to a significant competitive advantage for UCB and a smart investment in the technologically evolving gene therapy landscape.”

Furthermore, once the facility is complete UCB will operate sites in Belgium, China, Japan, Switzerland, Germany, US, and UK. And the firm claims the addition of this plant strengthens its gene therapy teams located in Braine/Leuven, Belgium, and Boston/Durham, US.

UCB said the facility will create 100 jobs in gene therapy, as well as offering its current employees fast-tracked career development. And the plant will support the company’s carbon neutral ambition, by using Building Research Establishment Environmental Assessment Method (BREEAM) certified to significantly reduce resource consumption and waste production.

About the Author

Millie Nelson

Editor, BioProcess Insider

Journalist covering global biopharmaceutical manufacturing and processing news and host of the Voices of Biotech podcast.

I am currently living and working in London but I grew up in Lincolnshire (UK) and studied in Newcastle (UK).

Got a story? Feel free to email me at [email protected]

You May Also Like